Tanya Stoyanova | Cancer Biology | Best Researcher Award

Published on by Shen Awards

Dr. Tanya Stoyanova | Cancer Biology | Best Researcher Award

University of California, Los Angeles, United States

Dr. Tanya Stoyanova is an accomplished Associate Professor with tenure in the Departments of Molecular and Medical Pharmacology and Urology at the University of California, Los Angeles (UCLA), where she also serves as Department Vice Chair for Inclusive Excellence. She earned a B.S. in Ecology and Environmental Protection from the Technical University of Varna, Bulgaria (2001), a B.S. in Biology from the University of Kansas, USA (2003), and a Ph.D. in Biochemistry and Molecular Genetics from the University of Illinois, Chicago (2009), followed by a prestigious postdoctoral fellowship in Cancer and Stem Cell Biology at UCLA under Prof. Owen Witte (2009–2015). Her professional experience spans roles at Stanford University as Assistant and later Associate Professor of Radiology (2015–2022), before returning to UCLA to assume leadership in cancer research and faculty governance. Dr. Stoyanova’s research interests focus on cancer biology, molecular pharmacology, stem cell biology, biomarker discovery, and targeted therapeutics, with emphasis on prostate, lung, and epithelial cancers. She has led multiple NIH and Department of Defense–funded projects exploring novel molecular targets such as Trop2, UCHL1, ATAD2, and GSTP1, advancing minimally invasive diagnostics and innovative treatment strategies. Skilled in molecular genetics, biochemistry, cancer model systems, and translational pharmacology, she has contributed extensively to high-impact journals including Nature Cancer, Science Advances, and Clinical and Translational Medicine, while serving on editorial boards for Frontiers in Oncology and The Prostate. Her distinguished honors include the NIH/NCI R37 MERIT Award, multiple Department of Defense Idea Development Awards, the Jonsson Comprehensive Cancer Center Ablon Scholars Award, the Neuroendocrine Tumor Research Foundation Pilot Award, and the Society of Basic Urologic Research Young Investigator Award. In conclusion, Dr. Stoyanova’s blend of academic excellence, research innovation, international collaboration, and commitment to mentorship and inclusivity positions her as a global leader in translational cancer research, with strong potential to further advance diagnostics and therapies that significantly impact healthcare outcomes.

Profiles: Scopus | ORCID | Google Scholar | Staff Page

Featured Publications

  1. Lee, J. K., Phillips, J. W., Smith, B. A., Park, J. W., Stoyanova, T., McCaffrey, E. F., … (2016). N-Myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cells. Cancer Cell, 29(4), 536–547.

  2. Liu, F., Vermesh, O., Mani, V., Ge, T. J., Madsen, S. J., Sabour, A., Hsu, E. C., … (2017). The exosome total isolation chip. ACS Nano, 11(11), 10712–10723.

  3. Rice, M. A., Malhotra, S. V., & Stoyanova, T. (2019). Second-generation antiandrogens: From discovery to standard of care in castration resistant prostate cancer. Frontiers in Oncology, 9, 801.

  4. Ghoochani, A., Hsu, E. C., Aslan, M., Rice, M. A., Nguyen, H. M., Brooks, J. D., … (2021). Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer. Cancer Research, 81(6), 1583–1594.

  5. Drake, J. M., Paull, E. O., Graham, N. A., Lee, J. K., Smith, B. A., Titz, B., Stoyanova, T., … (2016). Phosphoproteome integration reveals patient-specific networks in prostate cancer. Cell, 166(4), 1041–1054.

Jan Hendrik Muller | Oncology and Pathology | Best Researcher Award

Published on by Shen Awards

Mr. Jan Hendrik Muller | Oncology and Pathology | Best Researcher Award

University Clinic Hamburg Eppendorf | Germany

Mr. Jan Hendrik Müller is an accomplished researcher in molecular life sciences with a specialization in cancer proteomics and translational medicine. Currently pursuing his Ph.D. at the Institute of Pathology, University Medical Center Hamburg-Eppendorf, he has established himself as a promising scientist with expertise in cutting-edge proteomic technologies such as LC-MS/MS and mass spectrometry. His academic career reflects a strong foundation in molecular biology, proteomics, and life science research, supported by rigorous training at leading German institutions including the University of Hamburg and Leibniz University Hannover. Jan’s research focuses on understanding cancer biology at the proteomic level, with the aim of identifying novel biomarkers and therapeutic targets. Alongside his academic journey, he has contributed as a research assistant in internationally recognized groups, gaining practical experience in experimental oncology, T-cell research, and collaborative scientific projects. His involvement in both laboratory research and medical volunteer work highlights his dedication to bridging science and societal benefit. Beyond technical expertise, Jan brings leadership, adaptability, and teamwork to his professional profile, making him a well-rounded candidate for recognition. His ability to integrate scientific curiosity with practical applications positions him as a researcher with significant potential to impact both academia and medical science in the future.

Professional Profile

Education

Mr. Jan Hendrik Müller has pursued a progressive and rigorous academic journey in the field of life sciences, developing expertise in molecular biology, proteomics, and translational medicine. He began his higher education at Leibniz University Hannover, where he earned his Bachelor of Science (B.Sc.) in Life Science. During his undergraduate years, Jan developed proficiency in molecular biology techniques including PCR, protein isolation, and confocal microscopy. His bachelor’s thesis, titled “The effects of dextran sodium sulfate on the barrier function of epithelial cells,” allowed him to gain experience in cell culture and epithelial biology. Following this, Jan pursued his Master of Science (M.Sc.) in Molecular Life Science at the University of Hamburg, completing his degree with excellent academic standing. His master’s studies were research-oriented, involving advanced training in proteomics under the guidance of Prof. Dr. Hartmut Schlüter. His projects included mass spectrometry analysis of prostate cancer tissue, contributing to translational cancer research. Building upon this foundation, Jan is currently enrolled in a Doctor of Philosophy (Ph.D.) program at the University Medical Center Hamburg-Eppendorf, focusing on cancer proteomics and drug response profiling. His educational background demonstrates consistent excellence, hands-on laboratory expertise, and a strong commitment to advancing biomedical research.

Professional Experience

Mr. Jan Hendrik Müller’s professional experience demonstrates a balanced combination of academic research, laboratory training, and clinical exposure. Early in his career, he trained as a paramedic and served in hospital settings, gaining valuable insights into patient care and surgical assistance, particularly in orthopedic surgeries. These experiences nurtured his sense of responsibility and motivated his transition from clinical service to biomedical research. During his academic career, he worked as a Research Assistant in the laboratory of Prof. Dr. Hartmut Schlüter at the University Medical Center Hamburg-Eppendorf. There, he specialized in proteomic analysis of prostate cancer tissue using LC-MS/MS, gaining expertise in mass spectrometry, sample preparation, and proteomic pathway analysis. He also contributed to collaborative projects on T-cell immunotherapy, including viral transduction and functional assays for CAR-T-cell research. In addition, Jan has managed laboratory responsibilities such as cryobank administration and patient sample handling, demonstrating both technical and organizational skills. His professional development is also marked by active teamwork in multidisciplinary projects and community service in hospital environments. These diverse experiences highlight his ability to integrate clinical relevance with scientific discovery, making him a well-rounded researcher equipped for impactful contributions to cancer biology and translational medicine.

Research Interests

Mr. Jan Hendrik Müller’s research interests lie at the intersection of molecular biology, proteomics, and translational oncology. His primary focus is the proteomic profiling of cancer tissues, particularly prostate cancer, using advanced techniques such as liquid chromatography coupled with mass spectrometry (LC-MS/MS). Through this approach, he seeks to unravel the molecular mechanisms underlying cancer progression and drug responses, with the goal of identifying novel therapeutic targets and biomarkers for early diagnosis. In addition to cancer proteomics, Jan is also interested in immunotherapy research, having gained experience in CAR-T-cell biology, viral transduction methods, and T-cell functional assays. His broader research goals include integrating proteomic data with systems biology to provide holistic insights into cellular pathways affected by novel drug treatments. Beyond oncology, Jan shows interest in the applications of molecular life sciences in personalized medicine, aiming to develop strategies that bridge fundamental research with clinical application. His interdisciplinary approach reflects his commitment to collaborative science, combining expertise in molecular biology, analytical chemistry, and clinical medicine. Ultimately, his research interests highlight a forward-looking vision to contribute meaningfully to cancer research, drug development, and precision medicine.

Research Skills

Over the course of his academic and professional journey, Mr. Jan Hendrik Müller has developed a broad and advanced skill set in experimental life sciences and proteomics. His expertise includes molecular biology techniques such as PCR, protein production, blotting, and electrophoresis, alongside advanced cell culture methods, including the maintenance of various cell lines and epithelial barrier function analysis. He is proficient in high-level proteomic methodologies, particularly LC-MS/MS and mass spectrometry-based proteome analysis, enabling him to study complex biological samples with precision. In the field of immunology, he has acquired skills in isolation, expansion, and viral transduction of T-cells, as well as functional CAR-T-cell assays. Jan also has experience in fluorescence-activated cell sorting (FACS), confocal microscopy, and proteomic pathway analysis, demonstrating technical versatility. Beyond laboratory skills, he is proficient in bioinformatics tools such as ImageJ, Matlab, and LaTeX for data visualization and documentation. His certifications include Good Manufacturing Practices (GMP), further enhancing his competency in clinical-grade research. In addition, Jan has proven skills in teamwork, problem-solving, and communication, strengthened by his volunteer work in medical and community settings. Together, his research skills position him as a highly capable scientist ready to contribute to complex biomedical projects.

Awards and Honors

While still in the early stages of his academic career, Mr. Jan Hendrik Müller has already received recognition for his academic and professional excellence. During his Master of Science program at the University of Hamburg, he achieved excellent grades, including a distinction in several advanced courses. His bachelor’s and master’s theses received commendation for their originality and scientific rigor, particularly in the field of proteomics and epithelial biology. Jan has also been awarded a certificate in Good Manufacturing Practices (GMP), reflecting his adherence to the highest standards of laboratory and clinical research practices. In addition to formal recognition, his contribution to research projects under internationally respected mentors such as Prof. Dr. Hartmut Schlüter has allowed him to build a reputation as a promising scientist in proteomics research. His community service in hospital environments and volunteer platforms further demonstrate his commitment to societal well-being. While he has yet to receive large-scale international honors, his strong research foundation, combined with his growing publication record and academic contributions, suggests a career trajectory that will lead to greater recognition in the global scientific community in the near future.

Publication TOp Notes

  • High-level STING expression in tumour and inflammatory cells is linked to microsatellite instability and favourable tumour parameters in a cohort of over 1,900 colorectal cancer patients — 2025

  • A Tc1- and Th1-T-lymphocyte-rich tumor microenvironment is a hallmark of MSI colorectal cancer — 2025

  • Prognostic Impact and Spatial Interplay of Immune Cells in Urothelial Cancer — 2024

  • Loss of TROP2 and epithelial cell adhesion molecule expression is linked to grade progression in pTa but unrelated to disease outcome in pT2-4 urothelial bladder carcinomas — 2024

  • Automated Prognosis Marker Assessment in Breast Cancers Using BLEACH&STAIN Multiplexed Immunohistochemistry — 2023

Conclusion

In conclusion, Mr. Jan Hendrik Müller exemplifies the qualities of a dedicated and innovative young researcher in the field of molecular life sciences and cancer proteomics. His academic excellence, demonstrated through his bachelor’s, master’s, and ongoing Ph.D. studies, reflects his consistent pursuit of scientific knowledge and translational medicine. His professional experiences, ranging from hospital assistance to advanced cancer proteomic research, reveal a well-rounded individual capable of integrating clinical insights with laboratory discoveries. With expertise in proteomics, immunotherapy, and molecular biology, Jan has built a diverse skill set that positions him as a valuable contributor to biomedical science. His community involvement, volunteer medical service, and collaborative research engagements highlight his leadership qualities and social responsibility. While there is room for further recognition through expanded publications and global collaborations, his trajectory demonstrates great promise. Jan is not only contributing to cancer research but is also laying the foundation for impactful work in personalized medicine and future healthcare innovation. These achievements, combined with his dedication, make him a deserving candidate for recognition and a strong contender for future leadership in biomedical research.

Zhen Ma | Surgical Oncology | Best Researcher Award

Published on by Shen Awards

Dr. Zhen Ma | Surgical Oncology | Best Researcher Award

Chief Resident from The Second Hospital of Lanzhou University, China

Dr. Zhen Ma is a skilled surgical oncologist specializing in gastrointestinal malignancies with advanced training in minimally invasive and robotic surgical procedures. His professional practice centers at The Second Hospital of Lanzhou University, a Grade A tertiary institution in China, where he leads surgical interventions in gastric, hepatic, and colorectal cancers. In addition to his clinical responsibilities, Dr. Ma is a dedicated researcher whose work explores resistance mechanisms in gastrointestinal tumors and innovations in surgical technology. He has authored over seven first-author publications in reputable peer-reviewed journals, contributing to the growing body of knowledge in oncology and surgical techniques. Furthermore, Dr. Ma has played key roles in more than 16 phase I–III clinical trials related to advanced solid tumors, demonstrating his expertise in clinical trial management and cancer therapeutics. His ability to integrate clinical expertise with research insights positions him as an emerging leader in surgical oncology. He is fluent in medical English, possesses extensive training in research methodologies, and actively contributes to the evolution of cancer care in China. With ongoing involvement in national research projects, clinical innovations, and the development of surgical devices, Dr. Ma exemplifies the qualities of a modern clinician-scientist committed to translational medicine and precision oncology.

Professional Profile

Education

Dr. Zhen Ma has pursued a rigorous academic pathway that reflects his dedication to excellence in medicine and oncology. He earned his Bachelor of Medicine (B.M.) in Clinical Medicine from Wuhan University (2006–2011), one of China’s top medical institutions. Following this, he completed a Master of Medicine (M.M.) in Surgery at the prestigious Zhejiang University from 2012 to 2015, where he deepened his surgical skills and began his early clinical work. His academic journey culminated with a Ph.D. in Oncology, with a focus on digestive tract tumors, from Lanzhou University (2019–2024), an institution known for its cancer research in northwest China. His doctoral research has concentrated on chemoresistance mechanisms and autophagy-related genes in gastric cancer. Each academic phase has equipped Dr. Ma with a solid foundation in clinical medicine, advanced surgical practice, and scientific research. His education reflects a balance between practical surgical expertise and a sophisticated understanding of molecular oncology. By pursuing advanced degrees from diverse top-tier universities, Dr. Ma has gained a multidisciplinary academic background that enhances his ability to approach oncological challenges from both a clinical and research perspective.

Professional Experience

Dr. Zhen Ma has cultivated a comprehensive professional background as a practicing surgical oncologist and academic researcher. He began his medical career as a surgeon at The Second Hospital of Lanzhou University in 2015, where he initially focused on thyroid oncology using minimally invasive approaches. In 2018, he advanced to the position of attending surgeon in the Department of Surgical Oncology, specializing in the surgical management of gastric, colorectal, hepatic, and biliary tract cancers. He is proficient in Enhanced Recovery After Surgery (ERAS) protocols, which have significantly improved patient outcomes, reducing complications by 30%. He also pioneered the clinical use of indocyanine green (ICG) fluorescence navigation for bilioenteric anastomosis, lowering leakage rates to below 2%. In addition to his surgical work, Dr. Ma has inserted and maintained over 100 venous infusion ports to facilitate chemotherapy for cancer patients. His professional practice is marked by a blend of innovative surgical intervention, commitment to patient safety, and continuous adoption of cutting-edge techniques. He has also served as the lead surgeon in device innovation trials and co-investigator on national-level oncology research projects, illustrating his seamless integration of clinical excellence with medical innovation and translational research.

Research Interests

Dr. Zhen Ma’s research interests are rooted in gastrointestinal oncology, with a specific focus on molecular mechanisms of chemoresistance, autophagy-related gene signatures, and minimally invasive surgical innovations. His doctoral work investigates how autophagy influences prognosis and treatment outcomes in gastric and hepatocellular carcinomas. Dr. Ma is deeply engaged in translational research that bridges molecular biology with clinical application, exemplified by his participation in studies exploring gene markers for drug resistance and survival prediction. Additionally, he has developed an interest in robotic and laparoscopic techniques as part of enhancing surgical precision and patient recovery. His participation in numerous clinical trials, including phase III studies on SOX-based chemotherapy regimens and targeted immunotherapy agents such as camrelizumab, reflects his dedication to integrating novel systemic therapies into surgical oncology. Another critical area of his research includes medical device innovation, where he led clinical trials on laparoscopic endoscopic systems for splenectomy and thyroid surgery. Overall, Dr. Ma’s research demonstrates a comprehensive approach to cancer care that includes genetics, clinical treatment optimization, and real-time surgical navigation—all aimed at improving survival rates and quality of life for gastrointestinal cancer patients.

Research Skills

Dr. Zhen Ma possesses a strong portfolio of technical and research skills that support his role as a clinician-scientist. Technically, he is adept at laparoscopic and robotic surgical techniques, ICG fluorescence imaging, thyroidectomy, and venous port placement, which are core to his surgical oncology practice. On the research side, Dr. Ma is proficient in clinical trial design and execution, supported by his Good Clinical Practice (GCP) certification. He is skilled in molecular biology techniques that include autophagy-related gene analysis and immunological assessments—crucial for understanding tumor behavior and therapy resistance. In data analysis, Dr. Ma uses software such as SPSS and R for biostatistical modeling, survival analysis, and interpretation of clinical data. He also has experience drafting case reports, literature reviews, and scientific papers for international journals. His language proficiency in both Mandarin and medical English allows him to collaborate across institutions and contribute to global research discourse. These skills make him well-equipped to design impactful studies, evaluate complex datasets, and implement innovative surgical and medical interventions with academic rigor and ethical integrity.

Awards and Honors

Although specific national or international awards are not listed in the available information, Dr. Zhen Ma’s career achievements reflect honors of clinical innovation and research leadership. Notably, he is the lead inventor of two patents: one for an abdominal belt to prevent drainage tube compression, and another for a nutrition tube unblocking device, both granted in 2020. These inventions show his ability to translate bedside challenges into tangible medical devices, which is a hallmark of applied medical innovation. Additionally, his successful participation as a Principal Investigator (PI) and Sub-Investigator (Sub-I) in high-level multicenter clinical trials reflects recognition from the national research community and pharmaceutical collaborators. His role in government-funded research projects, such as the National Health Commission GI Tumor Lab and the NSFC dual liver transplant immunology study, signifies peer trust and institutional acknowledgment of his research capacity. Furthermore, his appointment as an attending surgeon at a Grade A tertiary hospital at a relatively early stage in his career highlights the institutional confidence in his clinical and academic capabilities. These achievements position him as an award-worthy researcher contributing meaningfully to clinical practice and surgical science.

Conclusion

Dr. Zhen Ma is a dedicated and forward-thinking surgical oncologist who integrates clinical excellence with research-driven innovation. With an academic background from top Chinese universities and clinical experience at a leading tertiary care hospital, he has built a robust foundation in both patient care and medical science. His research in autophagy and chemoresistance contributes valuable insights to gastrointestinal cancer management, while his involvement in clinical trials bridges cutting-edge therapies with real-world application. His technical innovations, including ICG-guided surgery and patented medical devices, further demonstrate his commitment to enhancing patient outcomes through practical solutions. Dr. Ma’s work exemplifies the principles of translational medicine—moving from bench to bedside with measurable impact. Though early in his academic career, he has already achieved notable success in publications, research leadership, and surgical outcomes. With potential for expanded international collaboration and high-impact research publication, Dr. Ma is well-positioned to continue advancing the field of surgical oncology. As such, he represents an ideal candidate for the Best Researcher Award, honoring both his past accomplishments and his promising future contributions to medicine and clinical science.

Publications Top Notes

1. Comparative investigation of early-onset gastric cancer
Authors: Ma Z, Liu X, Paul ME, Chen M, Zheng P, Chen H
Year: 2021

2. Real-time indocyanine green fluorescence technique reduces anastomotic leakage in bilioenteric anastomosis: A case report and literature review
Authors: Ma Z, Deng J, Ma B, Chen H
Year: 2023

3. Identification and verification of a prognostic autophagy-related gene signature in hepatocellular carcinoma
Authors: Ma Z, Chen M, Liu X, Cui H
Year: 2024

4. Robotic Versus Total Laparoscopic Splenectomy With Pericardial Devascularisation for Portal Hypertension: A Retrospective Cohort Study
Authors: Ma Z, Cui H, Gaoi L, Ma B, He P, Yu Y, Wang Y, Ma Y, Chen H
Year: 2025

5. Prevention of ERCP complications
Authors: Ma Z, Li X, et al.
Year: 2019

6. Liver transplantation in primary sclerosing cholangitis
Authors: Ma Z, Tao P, et al.
Year: 2018

Fatemeh Safari | Cancer Therapy | Women Researcher Award

Published on by Shen Awards

Assist Prof Dr. Fatemeh Safari | Cancer Therapy | Women Researcher Award

Associate Professor at University of Guilan, Iran

Dr. Fatemeh Safari is an accomplished academic and researcher currently serving as an Associate Professor at the University of Guilan, Iran. She holds a Ph.D. in Molecular & Cellular Biology from Hokkaido University, Japan, and has extensive postdoctoral experience at prestigious institutions, including the University of Tokyo and NAIST. Dr. Safari has made significant contributions to the field of microbiology and cancer research, with numerous publications in reputable journals and books. Her work explores the molecular mechanisms underlying cancer progression and treatment, focusing on the therapeutic potential of stem cell secretomes and natural compounds like green tea extracts. Awarded multiple fellowships, including the JSPS Fellowship and Monbukagakusho Scholarship, she has established herself as a leading researcher. Dr. Safari’s expertise is complemented by her commitment to mentoring students and her active involvement in academic collaborations. Her research continues to impact the scientific community, enhancing our understanding of cancer biology and potential therapies.

Profile

Education

Assistant Professor Dr. Fatemeh Safari holds a Ph.D. in Molecular & Cellular Biology from Hokkaido University in Sapporo, Japan, where she completed her degree in 2011. Prior to her doctoral studies, she earned a Master’s degree in Microbiology from the University of Tehran in 2005, further solidifying her foundational knowledge in the biological sciences. Dr. Safari began her academic journey with a Bachelor’s degree in Biology, obtained from the University of Shahid Beheshti in Tehran, Iran, in 1999. Her diverse educational background encompasses a strong focus on molecular and cellular mechanisms, equipping her with the expertise necessary for her research in cancer biology and regenerative medicine. Dr. Safari’s academic achievements reflect her commitment to advancing scientific knowledge and contributing to the fields of microbiology and molecular biology.

Professional Experience

Prof. Dr. Fatemeh Safari has extensive experience in academia and research. Currently, she serves as an Associate Professor at the University of Guilan, Iran, since September 2022, where she has made significant contributions to the field of Molecular and Cellular Biology. Prior to this role, she was an Assistant Professor at the same institution from September 2016 to 2022. Dr. Safari gained valuable research experience as a Postdoctoral Fellow at prestigious institutions in Japan, including NAIST from 2014 to 2015 and The University of Tokyo from 2012 to 2014. Earlier in her career, she worked as a Research Assistant at the University of Tehran from 2005 to 2007. Throughout her career, Dr. Safari has focused on innovative research in microbiology and cancer biology, publishing extensively in reputable journals and contributing to various collaborative research projects. Her academic journey reflects her dedication to advancing scientific knowledge and mentoring future generations of researchers.

Research Interest

Professor Dr. Fatemeh Safari’s research interests lie at the intersection of molecular and cellular biology, with a particular focus on cancer biology, stem cell therapy, and drug development. Her work delves into understanding the molecular mechanisms underlying cancer progression and the potential therapeutic effects of mesenchymal stem cell (MSC) secretomes on various cancer types, including breast and colon cancers. Dr. Safari’s research also explores the modulation of cellular signaling pathways by natural and synthetic compounds, aiming to develop innovative anti-cancer agents. Her investigations into molecular docking, drug synthesis, and the bioactivity of green tea extracts highlight her commitment to finding novel therapeutic approaches. Additionally, she is involved in the development of advanced methodologies, such as spheroid formation and co-culture systems, to study tumor microenvironments. Dr. Safari’s research is highly interdisciplinary, contributing to the fields of oncology, pharmacology, and biotechnology.

Research Skills

Prof. Dr. Fatemeh Safari possesses a diverse array of research skills that significantly contribute to her expertise in molecular and cellular biology. Her extensive experience in microbiology and cancer research equips her with a robust foundation in experimental design and methodology. Proficient in advanced techniques such as molecular docking, cell culture, and the development of in vitro cancer models, she adeptly investigates cellular signaling pathways and the effects of various compounds on cancer cell behavior. Dr. Safari’s analytical skills are demonstrated through her numerous publications, showcasing her ability to synthesize complex data and draw meaningful conclusions. Additionally, her familiarity with both traditional and innovative approaches in microbiology allows her to explore interdisciplinary research opportunities. As a result, she is not only a proficient researcher but also a valuable mentor to emerging scientists, fostering a collaborative and innovative research environment in her laboratory.

Award and Recognition

Prof. Dr. Fatemeh Safari is a distinguished academic in the field of Molecular & Cellular Biology, recognized for her significant contributions to cancer research. She holds a Ph.D. from Hokkaido University and has garnered prestigious fellowships, including the Monbukagakusho Scholarship and the Japan Society for the Promotion of Science Fellowship. As an Associate Professor at the University of Guilan, she has published over 30 research articles in reputable journals and co-authored several book chapters, focusing on the molecular mechanisms of cancer and the therapeutic potential of stem cell secretomes. Her innovative research has earned her recognition within the academic community, and she actively participates in international conferences, sharing her findings and insights. Prof. Dr. Safari’s dedication to advancing scientific knowledge, coupled with her mentorship of emerging researchers, underscores her impactful role in the scientific community, making her a deserving candidate for the Best Researcher Award.

Conclusion

Professor Dr. Fatemeh Safari is a distinguished academic and researcher in the field of Molecular & Cellular Biology, with significant contributions to cancer research and regenerative medicine. Her extensive educational background, including a Ph.D. from Hokkaido University, complements her impressive publication record, featuring numerous articles in reputable journals. As an Associate Professor at the University of Guilan, she has demonstrated leadership in academia while mentoring students and collaborating on innovative research projects. Dr. Safari’s research focuses on the therapeutic potential of human adipose-derived mesenchymal stem cells (hAMSCs) in cancer treatment, highlighting her commitment to advancing scientific knowledge. Her recognition through prestigious fellowships, such as the JSPS Fellowship, underscores her international standing in the scientific community. With her blend of expertise, experience, and a dedication to research excellence, Professor Dr. Fatemeh Safari is a strong candidate for the Best Researcher Award, embodying the qualities of a leading scholar in her field.

Publication Top Notes
  1. Exploring the dichotomy of the mesenchymal stem cell secretome: Implications for tumor modulation via cell-signaling pathways
    • Authors: Rasouli, M., Alavi, M., D’Angelo, A., Roudi, R., Safari, F.
    • Year: 2024
    • Journal: International Immunopharmacology
    • Volume/Page: 143, 113265
    • Citations: 0
  2. Synthesis, molecular docking study, MD simulation, ADMET, and drug likeness of new thiazolo[3,2-a]pyridine-6,8-dicarbonitrile derivatives as potential anti-diabetic agents
    • Authors: Aghahosseini, F., Bayat, M., Sadeghian, Z., Gheidari, D., Safari, F.
    • Year: 2024
    • Journal: PLoS ONE
    • Volume/Issue/Page: 19(9), e0306973
    • Citations: 0
  3. TCAA-promoted novel approach synthesis and in vitro anti-cancer activity evaluation of spiro[indolo[2,1-b]quinazoline-6,4′-pyrano[2,3-c]pyrazole]-5′-carboxamides
    • Authors: Sadeghian, Z., Bayat, M., Eskandari, M., Safari, F.
    • Year: 2024
    • Journal: Results in Chemistry
    • Volume/Page: 9, 101636
    • Citations: 1
  4. The suppression of cell motility through the reduction of FAK activity and expression of cell adhesion proteins by hAMSCs secretome in MDA-MB-231 breast cancer cells
    • Authors: Safari, F., Bararpour, S., Omidi Chomachaei, F.
    • Year: 2024
    • Journal: Investigational New Drugs
    • Volume/Issue/Page: 42(3), pp. 272–280
    • Citations: 1
  5. Regulation of Cellular-Signaling Pathways by Mammalian Proteins Containing Bacterial EPIYA or EPIYA-Like Motifs Predicted to be Phosphorylated
    • Authors: Rasouli, M., Safari, F., Sobhani, N., Alavi, M., Roudi, R.
    • Year: 2024
    • Journal: DNA and Cell Biology
    • Volume/Issue/Page: 43(2), pp. 74–84
    • Citations: 1
  6. IRTKS Elevation in Patients with Colon Cancer and the Curative Influences of Hamsc Secretome on Polarity and Invasion of HT-29 Colon Cancer Cells
    • Authors: Khodabandeh, A., Safari, F., Ebadi Zavieh, S., Mirzanejad, L.
    • Year: 2024
    • Journal: Regenerative Engineering and Translational Medicine
    • Citations: 0
  7. Harnessing Nanotechnology for Idarubicin Delivery in Cancer Therapy: Current Approaches and Future Perspectives
    • Authors: Safari, F., Jalalian, Y., Abdouss, H., Fathi-Karkan, S., Pandey, S.
    • Year: 2024
    • Journal: BioNanoScience
    • Citations: 2
  8. Synthesis, Molecular Docking, and Biological Evaluation of Pyridin-3-yl-Pyrimidin-2-yl-Triazole Derivatives as Anti-cancer Agents
    • Authors: Firoozpour, L., Moghimi, S., Fallah Barzegar, M.H., Safari, F., Foroumadi, A.
    • Year: 2024
    • Journal: Polycyclic Aromatic Compounds
    • Volume/Issue/Page: 44(3), pp. 2062–2076
    • Citations: 1
  9. Synthesis and Biological Evaluation of 12-Aryl-11-hydroxy-5,6-dihydropyrrolo[2″,1″:3′,4′]pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyridazine-8(9H)-one Derivatives as Potential Cytotoxic Agents
    • Authors: Barghi Lish, A., Foroumadi, A., Kolvari, E., Safari, F.
    • Year: 2023
    • Journal: ACS Omega
    • Volume/Issue/Page: 8(45), pp. 42212–42224
    • Citations: 1
  10. Evaluation of SgK269 expression in colon cancer patients and the effects of hAMSCs secretome on tumor invasion through SgK269/c-Src/p-P130Cas/p-Paxillin/p-ERK1/2 signaling pathway in HT-29 colon cancer cells
    • Authors: Safari, F., Ansari Dogaheh, F., Dadashi, H.
    • Year: 2023
    • Journal: 3 Biotech
    • Volume/Issue/Page: 13(11), 346
    • Citations: 1

 

 

Mohammad Reza (Nima) Darbandi | Breast Cancer | Best Researcher Award

Published on by Shen Awards

Mr. Mohammad Reza (Nima) Darbandi | Breast Cancer | Best Researcher Award

PhD candidate of University of Georgia, United States.

Nima Darbandi is a Ph.D. student in Computer Science at the University of Georgia, where he also serves as a research and teaching assistant. His research focuses on optimizing the llama.cpp framework and developing AI systems for domain detection using DNS logs. Nima has extensive experience in teaching subjects like Discrete Mathematics and Computer Networks. He has held various roles in the industry, including Linux Expert at Parspack Cloud Services, Consultant at Monenco Industry Group, and Chief Technical Officer at HamyarNet ISP. Nima’s research skills encompass AI, computer networks, and system administration, with a strong foundation in Network+, CCNA, and Linux Essentials. His contributions to artificial intelligence and disease treatment highlight his innovative approach and interdisciplinary expertise. He has been recognized with several awards, including the Outstanding Teaching Assistant Award from the University of Georgia.

Professional Profiles:

Education

Nima Darbandi is currently pursuing his Ph.D. in Computer Science at the University of Georgia, Athens, GA, USA, starting in the fall of 2022. He earned his M.S. in Information Technology from the Iran University of Science and Technology, Tehran, IRAN, where he conducted a dissertation titled “A New Method to Estimate QoE for Internet Users” from 2011 to 2015. Before that, he completed his B.S. in Information Technology at Shiraz University of Technology, Shiraz, IRAN, between 2006 and 2010.

Professional Experience

Nima Darbandi has a diverse professional background in both academia and industry. As a Research/Teaching Assistant at the University of Georgia, he worked on llama.cpp framework optimization and AI systems for DNS logs under Dr. Agrawal, Dr. Niu, and Dr. Perdisci from 2022 to 2024, while also teaching Discrete Mathematics and Computer Networks. In the industry, he served as a Linux Expert at Parspack Cloud Services in Tehran from 2021 to 2022, and as a Consultant for Monenco Industry Group from 2020 to 2022, where he developed a Dispatching System on CISCO telephony. Nima held the position of Chief Technical Officer at HamyarNet ISP from 2017 to 2020, overseeing ADSL and P2P wireless Internet services. He founded Puzzle Network Solutions, focusing on network services and devices, from 2014 to 2017, and was a Senior Manager at SabaNet ISP from 2009 to 2014. He also has extensive teaching experience, providing Network+, CCNA, Linux Essentials, and Computer Networking courses across several institutions in Shiraz from 2007 to 2018.

Research Interest

Nima Darbandi’s research interests lie primarily in the fields of computer science, information technology, and artificial intelligence. He is particularly focused on optimizing AI frameworks, such as llama.cpp, and utilizing AI for domain-specific applications like DNS log analysis. His work includes enhancing the quality of experience (QoE) for internet users, which was the subject of his M.S. dissertation. Nima is also interested in developing AI-driven solutions for early diagnosis and precision treatment in healthcare, as evidenced by his publication on AI breakthroughs in breast cancer treatment. Additionally, his research spans into network management, cloud hosting services, and cybersecurity, showcasing a broad interest in both theoretical and applied aspects of computing and technology.

Award and Honors

Nima Darbandi has received several awards and honors throughout his academic and professional career. In 2023, he was honored with the Outstanding Teaching Assistant Award from the University of Georgia, recognizing his excellence in teaching and support for students. In 2016, he received the Best Supporter and Advisor Token of Appreciation from Kavosh, highlighting his contributions and advisory role. Earlier, in 2013, he was awarded the Outstanding Network Expert Token of Appreciation from SabaNet ISP for his expertise and dedication in the field of network services. Additionally, in 2007, he secured the Third Rank Token of Appreciation from Shiraz University of Technology, acknowledging his academic achievements during his undergraduate studies. These accolades reflect his commitment to both teaching and technical proficiency.

 Research Skills

Nima Darbandi possesses a diverse set of research skills, honed through extensive academic and professional experiences. His expertise includes optimizing the llama.cpp framework and developing AI systems for domain detection using DNS logs. He is proficient in various aspects of computer networks, evidenced by his teaching roles in Discrete Mathematics and Computer Networks. His background in Linux, cloud hosting, and virtualization (VMware VCenter) further strengthens his technical prowess. Additionally, Nima has practical experience with Network+, CCNA, and Linux Essentials, reflecting his broad knowledge in networking and system administration. His research contributions in artificial intelligence, particularly in early diagnosis and precision treatment of diseases, underscore his interdisciplinary approach and innovation in the field.

 

 

Jaydira Del Rivero | Medical Oncology | Best Researcher Award

Published on by Shen Awards

Dr. Jaydira Del Rivero | Medical Oncology | Best Researcher Award

MD of NCI/NIH, United States.

Dr. Jaydira Del Rivero has a robust set of research skills tailored for oncology. Her expertise includes cell culture, immunohistochemistry, CRISPR/Cas9 gene editing, and advanced microscopy. Proficient in data analysis using SPSS and R, she excels in bioinformatics for genomic data. Dr. Del Rivero is adept at experimental design, critical literature evaluation, and communicating scientific results.

Professional Profiles:

Education

Dr. Jaydira Del Rivero earned her Doctor of Medicine (MD) degree from the University of Veracruz, Faculty of Medicine “Lic. Miguel Aleman Valdez” in October 2003. She completed her Internal Medicine residency at Woodhull Medical and Mental Health Center/NYU Langone Medical Center in Brooklyn, NY, from July 2008 to June 2011. Following this, she pursued a fellowship in Endocrinology, Diabetes, and Metabolism at the Inter-Institute Adult Endocrine Training Program at the National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, from July 2011 to June 2014. Dr. Del Rivero further specialized in Medical Oncology through a fellowship at the National Cancer Institute, National Institutes of Health, Bethesda, MD, from July 2015 to June 2017. Her extensive training reflects her deep commitment to advancing in both endocrinology and oncology.

Professional Experience

Dr. Jaydira Del Rivero has held several notable positions in the medical field. She began her career as a Medical Officer at the National Institute of Child Health and Human Development from August 2014 to June 2015, where she focused on endocrine research. Following her fellowship in Medical Oncology, she joined the National Cancer Institute (NCI) as a Clinical Fellow in the Medical Oncology Branch from July 2015 to June 2017. Since 2017, Dr. Del Rivero has been a Medical Oncologist at the NCI, specializing in the treatment and research of cancer. Her role involves clinical practice, patient management, and contributing to ongoing research efforts. Dr. Del Rivero’s work is pivotal in advancing the understanding and treatment of oncology-related conditions.

Research Interest

Dr. Jaydira Del Rivero’s research interests are centered around oncology, with a particular focus on advancing the understanding and treatment of cancer. Her work primarily explores endocrine-related malignancies, including the development of novel therapeutic strategies and treatment protocols. Dr. Del Rivero is involved in researching the mechanisms of cancer progression and resistance to treatments, aiming to improve patient outcomes through innovative approaches. Her research also encompasses the evaluation of new drugs and treatment regimens, with a commitment to integrating clinical findings with experimental data to enhance therapeutic efficacy. Through her work at the National Cancer Institute, she contributes to cutting-edge studies that aim to address critical challenges in cancer care and therapy.

Award and Honors

Dr. Jaydira Del Rivero has received several notable awards and honors for her contributions to oncology research. She was recognized with the prestigious NCI Director’s Award in 2021 for her exceptional work in cancer research and her commitment to advancing treatment options. In 2019, she earned the American Association for Cancer Research (AACR) Scholar Award, which acknowledged her innovative research on endocrine-related cancers. Additionally, Dr. Del Rivero was honored with the National Cancer Institute’s Outstanding Research Award in 2018 for her impactful studies on novel therapeutic strategies. Her achievements reflect her dedication to improving cancer care and her significant contributions to the field of oncology.

 Research Skills

Dr. Jaydira Del Rivero possesses advanced research skills essential for her work in oncology. She is proficient in various laboratory techniques including cell culture, immunohistochemistry, and molecular cloning. Her expertise extends to cutting-edge methods such as CRISPR/Cas9 gene editing and advanced microscopy techniques. Dr. Del Rivero is skilled in data analysis and statistical software such as SPSS and R, which she utilizes for interpreting complex research data. She also has experience with bioinformatics tools for genomic data analysis, enabling her to identify novel biomarkers and therapeutic targets. Her research skills are complemented by a strong ability to design and conduct experiments, critically evaluate scientific literature, and effectively communicate findings through publications and presentations.

Publications
  1. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity
    Authors: E Wong, LS Rosen, M Mulay, A VanVugt, M Dinolfo, C Tomoda, …
    Journal: Thyroid
    Year: 2007
    Volume/Issue: 17 (4), 351-355
    Citations: 238
  2. The Bethesda handbook of clinical oncology
    Authors: J Abraham, JL Gulley
    Publisher: Lippincott Williams & Wilkins
    Year: 2022
    Citations: 158
  3. Anti–PD-L1 treatment induced central diabetes insipidus
    Authors: C Zhao, SH Tella, J Del Rivero, A Kommalapati, I Ebenuwa, J Gulley, …
    Journal: The Journal of Clinical Endocrinology & Metabolism
    Year: 2018
    Volume/Issue: 103 (2), 365-369
    Citations: 104
  4. Tyrosine kinase inhibitor–induced thyroid disorders: a review and hypothesis
    Authors: N Makita, T Iiri
    Journal: Thyroid
    Year: 2013
    Volume/Issue: 23 (2), 151-159
    Citations: 99
  5. Resection versus expectant management of small incidentally discovered nonfunctional pancreatic neuroendocrine tumors
    Authors: AM Rosenberg, P Friedmann, J Del Rivero, SK Libutti, AM Laird
    Journal: Surgery
    Year: 2016
    Volume/Issue: 159 (1), 302-310
    Citations: 93
  6. Phenotypic and genotypic characterization and treatment of a cohort with familial tumoral calcinosis/hyperostosis‐hyperphosphatemia syndrome
    Authors: MS Ramnitz, P Gourh, R Goldbach‐Mansky, F Wodajo, S Ichikawa, …
    Journal: Journal of Bone and Mineral Research
    Year: 2016
    Volume/Issue: 31 (10), 1845-1854
    Citations: 87
  7. The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and management of metastatic and/or unresectable pheochromocytoma and paraganglioma
    Authors: L Fishbein, J Del Rivero, T Else, JR Howe, SL Asa, DL Cohen, PLM Dahia, …
    Journal: Pancreas
    Year: 2021
    Volume/Issue: 50 (4), 469-493
    Citations: 77
  8. Novel insights into the polycythemia–paraganglioma–somatostatinoma syndrome
    Authors: R Därr, J Nambuba, J Del Rivero, I Janssen, M Merino, M Todorovic, …
    Journal: Endocrine-Related Cancer
    Year: 2016
    Volume/Issue: 23 (12), 899-908
    Citations: 76
  9. Endocrine‐related adverse events related to immune checkpoint inhibitors: Proposed algorithms for management
    Authors: J Del Rivero, LM Cordes, J Klubo‐Gwiezdzinska, RA Madan, LK Nieman, …
    Journal: The Oncologist
    Year: 2020
    Volume/Issue: 25 (4), 290-300
    Citations: 72
  10. Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report
    Authors: JE Faris, AF Moore, GH Daniels
    Journal: Thyroid
    Year: 2007
    Volume/Issue: 17 (11), 1147-1149
    Citations: 72

 

 

Mohammed Kashani-Sabet | Oncology | Best Researcher Award

Published on by Shen Awards

Dr. Mohammed Kashani-Sabet | Oncology | Best Researcher Award

Medical Director, Oncology Service Line, Sutter Health at California Pacific Medical Center Research Institute, United States.

Dr. Mohammed Kashani-Sabet is a distinguished medical professional with extensive expertise in dermatology and oncology. Holding multiple leadership positions, including Medical Director of the Oncology Service Line at Sutter Health and the Cancer Center at California Pacific Medical Center, he has made significant contributions to cancer research and treatment. Dr. Kashani-Sabet received his medical education from renowned institutions such as Harvard University and the State University of New York at Stony Brook. Throughout his career, he has been involved in groundbreaking research focused on melanoma, cutaneous T-cell lymphoma, targeted therapy, and tumor biomarkers. He has received numerous honors and awards for his contributions to the field, including the Clinical Career Development Award from the Dermatology Foundation and the Patients’ Choice Award by Sutter Medical Network. Dr. Kashani-Sabet’s dedication to improving patient care and advancing cancer treatment has earned him widespread recognition and respect in the medical community.

Professional Profiles:

Education:

Dr. Mohammed Kashani-Sabet embarked on his academic journey with a Bachelor’s degree in Biochemical Sciences from Harvard University, followed by a Doctorate in Medicine from the State University of New York at Stony Brook. After completing his medical education, he undertook an internship in Internal Medicine and residency in Dermatology at the State University of New York at Stony Brook and the University of California, San Francisco (UCSF) respectively. Dr. Kashani-Sabet further honed his expertise through a post-doctoral fellowship in Cutaneous Oncology at UCSF’s Department of Dermatology and Division of Hematology/Oncology. This comprehensive educational background laid a robust foundation for his subsequent career as a renowned physician and researcher in the field of dermatology and oncology.

Professional Experience:

Dr. Mohammed Kashani-Sabet has held several prestigious positions throughout his career, demonstrating his leadership and expertise in the field of dermatology and oncology. Currently, he serves as the Medical Director of the Oncology Service Line at Sutter Health and as the Medical Director of the Cancer Center at California Pacific Medical Center. Additionally, he holds the position of Medical Director of the Center for Melanoma Research and Treatment at Sutter West Bay Medical Group, Sutter Pacific Medical Foundation, and California Pacific Medical Center. Dr. Kashani-Sabet also contributes significantly to research as a Senior Scientist at the California Pacific Medical Center Research Institute. His extensive professional experience spans over two decades and encompasses various roles in academia, clinical practice, and administrative leadership within prestigious institutions such as the University of California, San Francisco (UCSF) and the California Pacific Medical Center.

Research Focus:

Dr. Mohammed Kashani-Sabet’s research focus encompasses a broad spectrum of topics within dermatology and oncology, with a particular emphasis on melanoma and cutaneous T-cell lymphoma. His work includes investigating novel targeted therapies, such as ribozymes and siRNAs, for these malignancies. Additionally, he explores tumor metastasis, prognostic modeling, and tumor biomarkers to advance our understanding of these diseases and improve patient outcomes. Dr. Kashani-Sabet’s research efforts aim to translate scientific discoveries into clinical applications, with the ultimate goal of developing more effective treatments and interventions for patients with melanoma and cutaneous T-cell lymphoma.

Research Interest:

Dr. Mohammed Kashani-Sabet possesses a diverse set of research skills honed over years of experience in dermatology and oncology. His expertise includes clinical research, where he designs and conducts studies to evaluate novel therapies for melanoma and cutaneous T-cell lymphoma. In the laboratory, he is skilled in various techniques such as PCR, DNA sequencing, and gene expression analysis, essential for basic and translational research. Dr. Kashani-Sabet also excels in data analysis, utilizing statistical methods and software to interpret clinical and experimental data effectively. With a track record of publishing research findings in peer-reviewed journals, he demonstrates proficiency in scientific writing and manuscript preparation. Additionally, his ability to write grant proposals and collaborate with interdisciplinary teams underscores his commitment to advancing dermatologic oncology research and improving patient care.

Award and Honors:

Dr. Mohammed Kashani-Sabet has been recognized with numerous awards and honors throughout his career, reflecting his exceptional contributions to dermatologic oncology research and patient care. Among these accolades are the Clinical Career Development Award from the Dermatology Foundation in 1997 and the Herschel and Diana Zackheim Endowed Chair in Cutaneous Oncology in the same year. His dedication to teaching and mentorship was acknowledged with the Teacher of the Year Award in 2004, bestowed upon him by the Dermatology Residents at UCSF. Notably, Dr. Kashani-Sabet received the Patients’ Choice Award in 2013 from the Sutter Medical Network for achieving high patient satisfaction scores. His humanitarian efforts were recognized with the Humanitarian Award by the Melanoma Research Foundation in 2014. Moreover, he holds the Chair in Melanoma Research and Treatment at California Pacific Medical Center since 2015, a testament to his leadership and contributions to the field.

Publications:

  1. Pan-Cancer Pharmacogenomic Analysis of Patient-Derived Tumor Cells Using Clinically Relevant Drug Exposures
    • Authors: Chang, S.H., Ice, R.J., Chen, M., … Soroceanu, L., McAllister, S.D.
    • Citations: 0
    • Year: 2023
  2. Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing
    • Authors: Kashani-Sabet, M., Leachman, S.A., Stein, J.A., … Venna, S., Kirkwood, J.M.
    • Citations: 6
    • Year: 2023
  3. Improving Selection for Sentinel Lymph Node Biopsy among Patients with Melanoma
    • Authors: Miller, J.R., Lo, S.N., Nosrati, M., … Scolyer, R.A., Kashani-Sabet, M.
    • Citations: 3
    • Year: 2023
  4. Erratum: Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanoma
    • Authors: Dar, A.A., Bezrookove, V., Nosrati, M., … McAllister, S., Kashani-Sabet, M.
    • Citations: 0
    • Year: 2023
  5. Dual Targeting of EGFR and MTOR Pathways Inhibits Glioblastoma Growth by Modulating the Tumor Microenvironment
    • Authors: Sidorov, M., Dighe, P., Woo, R.W.L., … McAllister, S.D., Soroceanu, L.
    • Citations: 7
    • Year: 2023
  6. Extended long-term follow-up of metastatic melanoma patients treated with immunotherapy: late relapses and second primary melanomas
    • Authors: Minor, D.R., Kim, K.B., Karuturi, R.K.M., Kashani-Sabet, M.
    • Citations: 0
    • Year: 2023
  7. Lymphoscintigraphy Using Tilmanocept Detects Multiple Sentinel Lymph Nodes in Melanoma Patients
    • Authors: Balkin, D.M., Tranah, G.J., Wang, F., … Zager, J.S., Leong, S.P.
    • Citations: 0
    • Year: 2023
  8. BPTF promotes the progression of distinct subtypes of breast cancer and is a therapeutic target
    • Authors: Bezrookove, V., Khan, I.A., Nosrati, M., … Dar, A.A., Kashani-Sabet, M.
    • Citations: 3
    • Year: 2022
  9. Pitfalls and Rewards of Setting Up a Liquid Biopsy Approach for the Detection of Driver Mutations in Circulating Tumor DNAs: Our Institutional Experience
    • Authors: Chen, M., Jian, D., Sidorov, M., … McAllister, S.D., Desprez, P.-Y.
    • Citations: 2
    • Year: 2022
  10. Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanoma
    • Authors: Dar, A.A., Bezrookove, V., Nosrati, M., … McAllister, S., Kashani-Sabet, M.
    • Citations: 3
    • Year: 2022